Company profile
ENSYSCE BIOSCIENCES, INC.
NASDAQ:ENSCBiotechnology: Pharmaceutical Preparations
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05567354 | phase1 | completed | 2022-06-10 | 2022-08-31 | Ensysce Biosciences | A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103) |
| NCT05571345 | phase1 | completed | 2022-10-05 | 2022-12-23 | Ensysce Biosciences | A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104) |
| NCT06629402 | phase2 | completed | 2023-10-05 | 2023-11-14 | Ensysce Biosciences | Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201) |
| NCT05043766 | phase1 | completed | 2021-09-08 | 2022-03-21 | Ensysce Biosciences | Evaluation of Oral PF614 Relative to OxyContin (PF614-102) |
| NCT04406415 | phase1 | completed | 2020-09-21 | 2020-11-11 | Ensysce Biosciences | Oral Nafamostat in Healthy Volunteers (NAF-101) |
FDA applications (0)
No records yet.